A randomised, placebo-controlled, Phase II trial of adjuvant Avelumab in patients with stage I-III Merkel cell carcinoma

I-MAT will determine if a six-month treatment regime of Avelumab is well-tolerated and can eliminate residual microscopic cancer cells, thus reducing the risk of the cancer reoccurring and improving the overall outcomes for patients with early-stage Merkel cell carcinoma.

Primary Sponsor

Melanoma and Skin Cancer Trials Limited (MASC Trials)

Collaborating Groups

Trans Tasman Radiation Oncology Group (TROG)

Accrual Target

132

Expected Date of Accrual

June 2024

Trial Chairperson

Dr Wen Xu, Princess Alexandra Hospital, QLD, Australia

Trial Contact

imat@masc.org.au

Related Post

David, Jasmine and Susan Goode, re Kokoda Challenge to support TROG Cancer Research
27 May, 2025

Intrepid trekkers to take on Kokoda Challenge for TROG

LATEST NEWS: 27 May 2025 A team of five

Clinical Trials Day 2025 stand at Calvary Mater Newcastle
27 May, 2025

Clinical Trials Day celebrations help spread the work about TROG’s work

LATEST NEWS: 27 MAY 2025 TROG members and staff